Burford Brothers Inc. Grows Stock Position in Bristol Myers Squibb Company $BMY

Burford Brothers Inc. raised its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 210.3% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 23,457 shares of the biopharmaceutical company’s stock after acquiring an additional 15,897 shares during the period. Burford Brothers Inc.’s holdings in Bristol Myers Squibb were worth $1,352,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Norges Bank purchased a new position in Bristol Myers Squibb during the fourth quarter worth approximately $1,947,272,000. Primecap Management Co. CA purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter worth $1,436,115,000. Legal & General Group Plc acquired a new position in Bristol Myers Squibb in the second quarter valued at $980,862,000. AQR Capital Management LLC grew its position in Bristol Myers Squibb by 172.6% during the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after acquiring an additional 16,332,924 shares during the period. Finally, BlackRock Inc. increased its stake in Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Trading Up 0.6%

Shares of BMY opened at $68.06 on Friday. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $68.64. The stock’s 50-day moving average is $62.73 and its two-hundred day moving average is $59.87. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The stock has a market cap of $139.03 billion, a PE ratio of 14.99, a P/E/G ratio of 0.32 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.7%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on BMY. TD Cowen assumed coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating on the stock. Cantor Fitzgerald reissued a “neutral” rating and set a $59.00 target price (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the company an “equal weight” rating in a research report on Friday, July 31st. Finally, Argus upgraded shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective for the company in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $66.06.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Encouraging long-term data for Camzyos from the EXPLORER-LTE study supported renewed investor interest in the heart-failure drug. The data add to expectations that Camzyos can remain an important growth product for Bristol Myers Squibb. Bristol Myers Squibb Gains on Camzyos Data
• Positive Sentiment: Analysts and market commentators highlighted bullish technical indicators, strong recent returns, and Bristol Myers Squibb’s outperformance versus the broader healthcare sector. These factors may be attracting momentum-oriented investors. Revisiting Stock Picks
• Neutral Sentiment: RBC Capital maintained a Hold rating, reflecting a balanced view: BMY’s valuation and improving business momentum are constructive, but the stock’s strong run may already incorporate much of the favorable news. RBC Capital Maintains Hold Rating
• Negative Sentiment: Bristol Myers Squibb voluntarily paused enrollment in its zola-cel autoimmune cell-therapy trials after inflammatory side effects emerged during safety monitoring. The pause raises concerns about the therapy’s risk profile, delays a potentially important pipeline program, and may increase scrutiny of trial-disclosure practices. What Does the BMY Trial Pause Mean for Its Pipeline?
• Negative Sentiment: Broader reporting that Novartis and Bristol Myers Squibb halted autoimmune trials following deaths or serious side effects reinforces concerns about the safety and development risk of experimental cell therapies. Drugmakers Halt Autoimmune Trials

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.